Skip to content
2000
Volume 24, Issue 11
  • ISSN: 1871-5273
  • E-ISSN: 1996-3181

Abstract

Introduction

Gantenerumab (GR), a promising therapeutic agent for Alzheimer's disease (AD), has been the subject of extensive research. In this study, we aimed to provide a comprehensive analysis of the literature on GR.

Methods

A systematic search was conducted using the PubMed, Scopus, and Web of Science databases. VOSviewer and Bibliometrix were utilized to analyze bibliographic data.

Results

The analysis of the literature on GR revealed distinct publication trends. Reviews accounted for 52% of the records, followed by research articles (31%). The United States contributed the highest proportion of publications (26%). was the most prolific source (21 articles). The annual number of publications increased steadily from 2009 to 2024. Major international collaborations were observed among the United States, the United Kingdom, Switzerland, France, and Sweden. Research activity consistently centered on key themes, such as amyloid imaging, biomarkers, clinical trials, and β-amyloid. Thematic mapping identified specialized subfields, core research areas, and dynamic shifts in topics, offering a comprehensive overview of the GR research landscape.

Conclusion

GR-related literature showed sustained thematic focus, growing international collaboration, and a steady rise in publication volume within the field of AD. These findings highlight the continued need for clinical and biomarker-focused investigations to advance therapeutic development in AD.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/0118715273349645250324040257
2025-11-01
2025-12-31

  • From This Site

    /content/journals/cnsnddt/10.2174/0118715273349645250324040257
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ShippeeT. RosserB.R.S. WrightM.M. Scoping literature review: Experiences of sexual and gender minority older adults, with diagnoses of dementia, who use residential long-term services and supports.J. Appl. Gerontol.202343556257610.1177/07334648231213532 37975683
     [Google Scholar]
  2. GaoF. ChenJ. ZhouY. ChengL. HuM. WangX. Recent progress of small-molecule-based theranostic agents in Alzheimer’s disease.RSC Med. Chem.202314112231224510.1039/D3MD00330B 37974955
     [Google Scholar]
  3. BohrmannB. BaumannK. BenzJ. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.J. Alzheimers Dis.2012281496910.3233/JAD‑2011‑110977 21955818
     [Google Scholar]
  4. BloomD.E. LucaD.L. The global demography of aging: facts, explanations, future.Handbook of the economics of population aging.New York: Elsevier20161356
     [Google Scholar]
  5. NanousiV. KalogerakiK. SmyrnaiouA. TolaM. BokariF. GeorgopoulosV.C. The development of a pilot app targeting short-term and prospective memory in people diagnosed with dementia.Behav. Sci. (Basel)202313975210.3390/bs13090752 37754030
     [Google Scholar]
  6. DunnG. Knowledge, attitudes, and expectations among certified Nursing Assistants providing oral care to individuals with Alzheimer’s Disease or another form of Dementia utilizing Music Therapy.In: EWU Masters Thesis Collection. Master of Science (MS) in Dental Hygiene2022752
     [Google Scholar]
  7. KleinG. DelmarP. VoyleN. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis.Alzheimers Res. Ther.201911110110.1186/s13195‑019‑0559‑z 31831056
     [Google Scholar]
  8. OstrowitzkiS. DeptulaD. ThurfjellL. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.Arch. Neurol.201269219820710.1001/archneurol.2011.1538 21987394
     [Google Scholar]
  9. OstrowitzkiS. LasserR.A. DorflingerE. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease.Alzheimers Res. Ther.2017919510.1186/s13195‑017‑0318‑y 29221491
     [Google Scholar]
  10. SallowayS. FarlowM. McDadeE. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease.Nat. Med.20212771187119610.1038/s41591‑021‑01369‑8 34155411
     [Google Scholar]
  11. SöderbergL. JohannessonM. NygrenP. Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease.Neurotherapeutics202320119520610.1007/s13311‑022‑01308‑6 36253511
     [Google Scholar]
  12. XiangX. WernerG. BohrmannB. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance.EMBO Mol. Med.201689992100410.15252/emmm.201606370 27402340
     [Google Scholar]
  13. AlkhammashR. Bibliometric, network, and thematic mapping analyses of metaphor and discourse in COVID-19 publications from 2020 to 2022.Front. Psychol.202313106294310.3389/fpsyg.2022.1062943 36726506
     [Google Scholar]
  14. BérdiM. Bibliometric analysis of Hungarian-related publications in suicidal behavior research of the last three decades.Psychiatr. Hung.2023383189202 37982267
     [Google Scholar]
  15. BurnhamJ.F. Scopus database: a review.Biomed. Digit. Libr.2006311810.1186/1742‑5581‑3‑1 16522216
     [Google Scholar]
  16. WangS. ScellsH. KoopmanB. ZucconG. Automated MeSH Term Suggestion for Effective Query Formulation in Systematic Reviews Literature Search.In: Intell Syst Appli.20221620014110.1016/j.iswa.2022.200141
     [Google Scholar]
  17. AriaM. CuccurulloC. bibliometrix: An R-tool for comprehensive science mapping analysis.J. Informetrics201711495997510.1016/j.joi.2017.08.007
     [Google Scholar]
  18. Van EckN. WaltmanL. Software survey: VOSviewer, a computer program for bibliometric mapping.Scientometrics201084252353810.1007/s11192‑009‑0146‑3 20585380
     [Google Scholar]
  19. ArrudaH. SilvaE.R. LessaM. ProençaD.Jr BartholoR. VOSviewer and bibliometrix.J. Med. Libr. Assoc.2022110339239510.5195/jmla.2022.1434 36589296
     [Google Scholar]
  20. ArndtJ.W. QianF. SmithB.A. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β.Sci. Rep.201881641210.1038/s41598‑018‑24501‑0 29686315
     [Google Scholar]
  21. LinseS. ScheidtT. BernfurK. Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies.Nat. Struct. Mol. Biol.202027121125113310.1038/s41594‑020‑0505‑6 32989305
     [Google Scholar]
  22. JacobsenH. OzmenL. CarusoA. Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.J. Neurosci.20143435116211163010.1523/JNEUROSCI.1405‑14.2014 25164658
     [Google Scholar]
  23. BatemanR.J. SmithJ. DonohueM.C. Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease.N. Engl. J. Med.2023389201862187610.1056/NEJMoa2304430 37966285
     [Google Scholar]
  24. ChenC.D. McCulloughA. GordonB. Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease.Eur. J. Nucl. Med. Mol. Imaging20235092669268210.1007/s00259‑023‑06209‑0 37017737
     [Google Scholar]
  25. KleinG. DelmarP. KerchnerG.A. Thirty-six-month amyloid positron emission tomography results show continued reduction in amyloid burden with subcutaneous gantenerumab.J. Prev. Alzheimers Dis.2020811410.14283/jpad.2020.68 33336218
     [Google Scholar]
  26. PortronA. JordanP. DraperK. A phase I study to assess the effect of speed of injection on pain, tolerability, and pharmacokinetics after high-volume subcutaneous administration of gantenerumab in healthy volunteers.Clin. Ther.2020421108120.e110.1016/j.clinthera.2019.11.015 31883703
     [Google Scholar]
  27. LinnenlueckeM.K. MarroneM. SinghA.K. Conducting systematic literature reviews and bibliometric analyses.Aust. J. Manag.202045217519410.1177/0312896219877678
     [Google Scholar]
  28. LiuY. ZhaoL. ChenF. Comparative efficacy and safety of multiple acupuncture therapies for post stroke cognitive impairment: a network meta-analysis of randomized controlled trials.Front. Neurol.202314121809510.3389/fneur.2023.1218095 37638181
     [Google Scholar]
  29. MahamanY.A.R. EmbayeK.S. HuangF. Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention.Ageing Res. Rev.20227410154410.1016/j.arr.2021.101544 34933129
     [Google Scholar]
  30. Singh GautamA. PandeyS.K. LasureV. DubeyS. SinghR.K. Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies.Expert Opin. Biol. Ther.202323760361810.1080/14712598.2023.2227378 37334564
     [Google Scholar]
  31. MukhopadhyayS. BanerjeeD. A primer on the evolution of aducanumab: the first antibody approved for treatment of Alzheimer’s disease.J. Alzheimers Dis.20218341537155210.3233/JAD‑215065 34366359
     [Google Scholar]
  32. ZhuC. TongP. SongZ. A bibliometric and visual analysis of environmental behavior research.Sustainability (Basel)202113181033810.3390/su131810338
     [Google Scholar]
  33. AhmadT. MuradM.A. NasirS. MusaT.H. BaigM. HuiJ. Trends in hepatitis A research indexed in the Web of Science: a bibliometric analysis over the period from 1985 to 2019.Hum. Vaccin. Immunother.20211793221322910.1080/21645515.2021.1914804 33945397
     [Google Scholar]
  34. BeckS. BergenholtzC. BogersM. The Open Innovation in Science research field: A collaborative conceptualisation approach.Ind. Innov.202229213618510.1080/13662716.2020.1792274
     [Google Scholar]
  35. PanzaF. LozuponeM. SeripaD. ImbimboB.P. Amyloid‐β immunotherapy for Alzheimer disease: Is it now a long shot?Ann. Neurol.201985330331510.1002/ana.25410 30635926
     [Google Scholar]
  36. PanzaF. SeripaD. LozuponeM. The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset.Expert Opin. Biol. Ther.2018181253510.1080/14712598.2018.1389885 29037101
     [Google Scholar]
  37. PanzaF. SolfrizziV. ImbimboB.P. Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease.Expert Rev. Neurother.201414997398610.1586/14737175.2014.945522 25081412
     [Google Scholar]
  38. RehmanS.U. FarooqR.K. AshiqM. SiddiqueN. AhmadS. Bibliometric analysis of coronavirus disease (COVID-19) literature published in Web of Science 2019-2020.J. Family Community Med.20212811710.4103/jfcm.JFCM_332_20 33679183
     [Google Scholar]
  39. YounB.Y. SongH.J. YangK. Bibliometric analysis of integrative medicine studies from 2000 to 2019.Am. J. Chin. Med.202149482984110.1142/S0192415X21500397 33829965
     [Google Scholar]
  40. Pritish BaskaranT.B. GuptaM.K. RaghavP. NaveenK.H. GoelA.D. Exploring frailty and its domains - Systematic mapping of the literature.Indian J. Public Health202367114114710.4103/ijph.ijph_962_22 37039219
     [Google Scholar]
  41. RosenberryT.L. ZhouH.X. StaggS.M. ParavastuA.K. Oligomer formation by amyloid-β42 in a membrane-mimicking environment in Alzheimer’s disease.Molecules20222724880410.3390/molecules27248804 36557940
     [Google Scholar]
  42. DecourtB. BoumelhemF. PopeE.D.III ShiJ. MariZ. SabbaghM.N. Critical appraisal of amyloid lowering agents in AD.Curr. Neurol. Neurosci. Rep.20212183910.1007/s11910‑021‑01125‑y 34110536
     [Google Scholar]
  43. SpauwenP.J.J. van EupenM.G.A. KöhlerS. Associations of advanced glycation end-products with cognitive functions in individuals with and without type 2 diabetes: the maastricht study.J. Clin. Endocrinol. Metab.2015100395196010.1210/jc.2014‑2754 25459912
     [Google Scholar]
  44. YaffeK. LindquistK. SchwartzA.V. Advanced glycation end product level, diabetes, and accelerated cognitive aging.Neurology201177141351135610.1212/WNL.0b013e3182315a56 21900628
     [Google Scholar]
  45. BrundelM. KappelleL.J. BiesselsG.J. Brain imaging in type 2 diabetes.Eur. Neuropsychopharmacol.201424121967198110.1016/j.euroneuro.2014.01.023 24726582
     [Google Scholar]
  46. FasoulaN.A. XieY. KatsouliN. Clinical and translational imaging and sensing of diabetic microangiopathy: a narrative review.J. Cardiovasc. Dev. Dis.202310938310.3390/jcdd10090383 37754812
     [Google Scholar]
  47. ShiM. ChuF. ZhuF. ZhuJ. Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer’s disease: a focus on aducanumab and lecanemab.Front. Aging Neurosci.20221487051710.3389/fnagi.2022.870517 35493943
     [Google Scholar]
  48. DecourtB. NoordaK. NoordaK. ShiJ. SabbaghM.N. Review of advanced Drug Trials Focusing on the reduction of brain Beta-Amyloid to prevent and treat dementia.J. Exp. Pharmacol.20221433135210.2147/JEP.S265626 36339394
     [Google Scholar]
  49. SilvestroS. ValeriA. MazzonE. Aducanumab and its effects on tau pathology: is this the turning point of amyloid hypothesis?Int. J. Mol. Sci.2022234201110.3390/ijms23042011 35216126
     [Google Scholar]
  50. CummingsJ. AisenP. ApostolovaL.G. AtriA. SallowayS. WeinerM. Aducanumab: appropriate use recommendations.J. Prev. Alzheimers Dis.202184398410 34585212
     [Google Scholar]
  51. VitekG.E. DecourtB. SabbaghM.N. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease.Expert Opin. Investig. Drugs2023322899410.1080/13543784.2023.2178414 36749830
     [Google Scholar]
  52. RahmanA. HossenM.A. ChowdhuryM.F.I. Aducanumab for the treatment of Alzheimer’s disease: a systematic review.Psychogeriatrics202323351252210.1111/psyg.12944 36775284
     [Google Scholar]
  53. AvilaJ. LucasJ.J. PérezM. HernándezF. Role of tau protein in both physiological and pathological conditions.Physiol. Rev.200484236138410.1152/physrev.00024.2003 15044677
     [Google Scholar]
  54. JouanneM. RaultS. Voisin-ChiretA.S. Tau protein aggregation in Alzheimer’s disease: An attractive target for the development of novel therapeutic agents.Eur. J. Med. Chem.201713915316710.1016/j.ejmech.2017.07.070 28800454
     [Google Scholar]
  55. PîrşcoveanuD.F.V. PiriciI. TudoricăV. Tau protein in neurodegenerative diseases - a review. Romanian journal of morphology and embryology =.Rev. Roum. Morphol. Embryol.20175811411150
     [Google Scholar]
  56. KotraL.P. ParkJ. Chapter 5.14 -Therapeutic Approaches to MS and Other Neurodegenerative Diseases. ChackalamannilS. RotellaD. WardS.E. Comprehensive Medicinal Chemistry III.Oxford: Elsevier201743947310.1016/B978‑0‑12‑409547‑2.13766‑7
     [Google Scholar]
/content/journals/cnsnddt/10.2174/0118715273349645250324040257
Loading
Trends in Research on Gantenerumab for Alzheimer’s Disease: A Bibliometric and Thematic Analysis
CNS Neurol. Disord. Drug Targets 24, 833 (2025); https://doi.org/10.2174/0118715273349645250324040257
/content/journals/cnsnddt/10.2174/0118715273349645250324040257
/content/journals/cnsnddt/10.2174/0118715273349645250324040257
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Alzheimer's disease; amyloid-beta; bibliometric analysis; biomarkers; clinical trials; cognitive decline; Gantenerumab

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test